



LIST OF TABLES

TABLE NO.	TITLE	PAGE
2.1	Definitions of lung volumes and capacities describing pulmonary ventilation	9
2.2	Factors that may affect the pulmonary absorption rate and bioavailability	19
2.3	Commercially available DPIs and new DPIs currently under development its dispersion mechanism	23
2.4	US FDA requirements for testing Dry Powder Inhalers	33
2.5	Major modes of liposomal action and related applications	47
3.1	Calibration curve for the estimation of AMK	93
3.2	Calibration curve for the estimation of AMK in biological fluids	96
3.3	Calibration curve for the estimation of PC	98
3.4	Calibration curve for the estimation of Chol	100
3.5	Interference of excipients used in the formulations	103
3.6	Calibration curve for the estimation of AMB	106
3.7	Calibration curve for the estimation of AMB in biological fluids	108
4.1	Optimization of liposomal AMK preparation by TFH method	128
4.2	Optimization of liposomal AMK preparation by REV method	129
4.3	Optimization of liposomal AMB preparation by TFH method	130
4.4	Optimization of liposomal AMB preparation by REV method	131
4.5	Effect of process variables on formation of liposomal AMK and AMB	134
4.6	Trapped volume of liposomal dispersions prepared with optimal process and formulation variables	144

4.7	Particle size range of liposomal batches at various stages of preparation	145
5.1	Selection and optimization of cryoprotectant for efficient lyophilization of AMK liposomes	164
5.2	Selection and optimization of cryoprotectant for efficient lyophilization of AMB liposomes	165
5.3	Optimization of AMK LDPI formulation	169
5.4	Comparative characterization of potential batches of AMK LDPI formulations	170
5.5	Optimization of AMB LDPI formulation	172
5.6	Comparative characterization of potential batches of AMB LDPI formulations	173
5.7	Essential formulation components of the LDPI batches selected for the further studies	175
5.8	Characterization of LDPI formulations	177
5.9	Particle size range of LDPI formulations	179
6.1	Drug leakage profiles of LDPI formulations of AMK	196
6.2	Drug leakage profiles of LDPI formulations of AMB	199
6.3	Mean liposomal size range of LDPI formulations at different storage time and conditions	203
7.1	Comparative in vitro drug diffusion of Optimized LDPI formulations	212
7.2	Regression coefficient (r) of the line of percent drug released Vs square root of time	216
7.3	Mean flux and Diffusion coefficient values of optimized liposomal formulations across artificial membrane	217
8.1	Drug level in biological samples following instillation of liposomal DPI of AMK and plain drug	227
8.2	Drug level in biological samples following instillation of liposomal DPI of AMB and plain drug formulation	229
8.3	Mean Pharmacokinetic parameters of liposomal formulation comparative to plain drug	232